Application No.: 10/001945 Docket No.: PPI-106CP2

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of the claims and listing of the claims in the application:

1. (Currently Amended) A compound of Formula I,



(I)

wherein

A is a Met-AP2 inhibitory core;

W is O or $NR_2$;

$R_1$ and $R_2$ are each, independently, hydrogen or alkyl;

X is alkylene or substituted alkylene;

n is 0 or 1;

$R_3$ and $R_4$ are each, independently, substituted alkyl, substituted aryl or substituted or unsubstituted heteroaryl; or $R_3$ and $R_4$, together with the carbon atom to which they are attached, form a carbocyclic or heterocyclic group; or $R_3$ and $R_4$ together form an alkylene group;

Z is -C(O)-, alkylene or alkylene-C(O)-; and

P is a peptide comprising from 1 to about 100 amino acid residues attached at its amino terminus to Z or a group $OR_5$ or $N(R_6)R_7$, wherein

$R_5$, $R_6$ and $R_7$ are each, independently, hydrogen, alkyl, substituted alkyl, azacycloalkyl or substituted azacycloalkyl; or $R_6$ and $R_7$, together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heterocyclic ring structure;

or

Z is -O-, $-NR_8$-, alkylene-O- or alkylene-$NR_8$-, where $R_8$ is hydrogen or alkyl; and

P is hydrogen or a peptide consisting of from 1 to about 100 amino acid residues attached at its carboxy terminus to Z; wherein

the N-terminus of the peptide is ~~$-NR_2R_3$~~ $-NR_2'R_3'$ wherein ~~$R_2$~~-$R_2'$ is hydrogen, alkyl or arylalkyl and ~~$R_3$~~ $R_3'$ is hydrogen, alkyl, arylalkyl or acyl.

2. (Currently Amended) The compound of claim 1, wherein at least one of ~~$R_1$,~~ $R_3$ and $R_4$ is a substituted ~~or unsubstituted~~ alkyl group.

3. (Currently Amended) The compound of claim 2, wherein at least one of ~~$R_1$,~~ $R_3$ and $R_4$ is a substituted ~~or unsubstituted~~ normal, branched or cyclic $C_1$-$C_6$ alkyl group.

4. (Currently Amended) The compound of claim 3, wherein at least one of ~~$R_1$,~~ $R_3$ and $R_4$ is a substituted normal or branched $C_1$-$C_4$ alkyl group.

5. (Currently Amended) The compound of claim 1, wherein one of $R_3$ and $R_4$ is a substituted ~~or unsubstituted~~ aryl group, a substituted or unsubstituted heteroaryl group, or a substituted or unsubstituted heteroarylalkyl group~~, or a substituted or unsubstituted aryl alkyl group~~.

6. (Currently Amended) The compound of claim 5, wherein one of $R_3$ and $R_4$ is selected from the group consisting of ~~phenyl, naphthyl,~~ indolyl, imidazolyl, pyridyl, ~~benzyl, naphthylmethyl~~, indolylmethyl, imidazolylmethyl and pyridylmethyl.

7. (Original) The compound of claim 1, wherein n is 1 and X is $C_1$-$C_6$-alkylene.

8. (Original) The compound of claim 7, wherein X is methylene or ethylene.

9. (Original) The compound of claim 1, wherein Z is $C_1$-$C_6$-alkylene-C(O)-.

10. (Original) The compound of claim 9, wherein Z is methylene-C(O)- or ethylene-C(O)-.

11. (Previously Presented) The compound of claim 1, wherein at least one of $R_6$ and $R_7$ is alkyl, substituted alkyl, substituted or unsubstituted azacycloalkyl or substituted or unsubstituted azacycloalkylalkyl.

12. (Original) The compound of claim 11, wherein at least one of $R_6$ and $R_7$ is an azacycloalkyl group having an N-alkyl substituent.

13. (Original) The compound of claim 12, wherein the N-alkyl substituent is a $C_1$-$C_4$-alkyl group.

14. (Original) The compound of claim 13, wherein the N-alkyl substituent is a methyl group.

15. (Original) The compound of claim 1, wherein $R_6$ and $R_7$, together with the nitrogen atom to which they are attached, form a substituted or unsubstituted five or six-membered aza- or diazacycloalkyl group.

16. (Original) The compound of claim 15, wherein $R_6$ and $R_7$, together with the nitrogen atom to which they are attached, form a substituted or unsubstituted five or six-membered diazacycloalkyl group which includes an N-alkyl substituent.

17. (Original) The compound of claim 16, wherein the N-alkyl substituent is a $C_1$-$C_4$-alkyl group.

18. (Original) The compound of claim 17, wherein the N-alkyl substituent is a methyl group.

19. (Currently Amended) The compound of claim 1, wherein P is $NH_2$ or one of the groups shown below:





20.-56. (Cancelled)

57. (Currently Amended) An angiogenesis inhibitor compound selected from the group consisting of

~~N-Carbamoyl-GlyArgGlyAspSerPro-(3*R*, 4*S*, 5*S*, 6*R*)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-butyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;~~

~~N-Carbamoyl-GlyArgGlyAspTyr(OMe)ArgGlu-(3*R*, 4*S*, 5*S*, 6*R*)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-butyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;~~

~~N-Carbamoyl-GlyArgGlyAsp-(3*R*, 4*S*, 5*S*, 6*R*)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-butyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;~~

~~N-Carbamoyl-GlyArgGlyAsp-(3*R*, 4*S*, 5*S*, 6*R*)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;~~

~~N-Carbamoyl-GlyArg-[3-amino-3(pyridyl)]-propionic acid-(3*R*, 4*S*, 5*S*, 6*R*)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;~~

~~N-Carbomoyl-GlyProLeuGly (3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2R,3R) 2-methyl-3-(3-methyl-but-2-enyl) oxiranyl] 1-oxa-spiro[2.5]oct-6-yl ester;~~

~~Ac-ProLeuMetTrpAla (2*R*-[(3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2R,3R) 2-methyl-3-(3-methyl-but-2-enyl) oxiranyl] 1-oxa-spiro[2.5]oct-6-yloxycarbonyl}-amino-3-methyl-butanol) ester;~~

~~Ac-ProLeuGlyMet (2*R*-[(3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2R,3R) 2-methyl-3-(3-methyl-but-2-enyl) oxiranyl] 1-oxa-spiro[2.5]oct-6-yloxycarbonyl}-amino-3-methyl-butanol) ester;~~

~~Ac-ProLeuGlyMetAla 2*R*-[(3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2R,3R) 2-methyl-3-(3-methyl-but-2-enyl) oxiranyl] 1-oxa-spiro[2.5]oct-6-yloxycarbonyl}-amino-3-methyl-butanol) ester;~~

{2-Methyl-1-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-propyl}-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;

[1-(2-Dimethylamino-ethylcarbamoyl)-2-methyl-propyl]-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;

{1-[(2-Dimethylamino-ethyl)-methyl-carbamoyl]-2-methyl-propyl}-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;

[1-(3-Dimethylamino-propylcarbamoyl)-2-methyl-propyl]-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;

[1-(3-Dimethylamino-2,2-dimethyl-propylcarbamoyl)-2-methyl-propyl]-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;

[2-Methyl-1-(4-methyl-piperazine-1-carbonyl)-propyl]-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;

{2-Methyl-1-[2-(1-methyl-pyrrolidin-2-yl)-ethylcarbamoyl]-propyl}-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;

[2-Methyl-1-(4-pyrrolidin-1-yl-piperidine-1-carbonyl)-propyl]-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester; and

[1-(4-Benzyl-piperazine-1-carbonyl)-2-methyl-propyl]-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester.

58.-61. (Cancelled)

62. (Currently Amended) A method of treating an angiogenic disease in a subject, comprising administering to the subject a therapeutically effective amount of an angiogenesis inhibitor compound comprising the structure



wherein

A is a Met-AP2 inhibitory core;

W is O or $NR_2$;

$R_1$ and $R_2$ are each, independently, hydrogen or alkyl;

X is alkylene or substituted alkylene;

n is 0 or 1;

$R_3$ and $R_4$ are each, independently, ~~hydrogen,~~ substituted ~~or unsubstituted~~ alkyl, substituted ~~or unsubstituted~~ aryl or substituted or unsubstituted heteroaryl; or $R_3$ and $R_4$, together with the carbon atom to which they are attached, form a carbocyclic or heterocyclic group; or $R_3$ and $R_4$ together form an alkylene group;

Z is -C(O)-, alkylene or alkylene-C(O)-; and

P is a peptide comprising from 1 to about 100 amino acid residues attached at its amino terminus to Z or a group $OR_5$ or $N(R_6)R_7$, wherein

$R_5$, $R_6$ and $R_7$ are each, independently, hydrogen, alkyl, substituted alkyl, azacycloalkyl or substituted azacycloalkyl; or $R_6$ and $R_7$, together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heterocyclic ring structure;
or
Z is -O-, -$NR_8$-, alkylene-O- or alkylene-$NR_8$-, where $R_8$ is hydrogen or alkyl; and
P is hydrogen or a peptide consisting of from 1 to about 100 amino acid residues attached at its carboxy terminus to Z; wherein
the N-terminus of the peptide is $-NR_{2'}R_{3'}$ wherein $R_{2'}$ is hydrogen, alkyl or arylalkyl and $R_{3'}$ is hydrogen, alkyl, arylalkyl or acyl.

63. (Original) The method of claim 62, wherein said angiogenic disease is an autoimmune disease.

64. (Original) The method of claim 63, wherein said autoimmune disease is rheumatoid arthritis.

65. (Original) The method of claim 62, wherein said angiogenic disease is cancer.

66. (Non-Entered Claim) The compound of claim 1, wherein $R_1$ is a substituted or unsubstituted alkyl group.

67. (Non-Entered Claim) The compound of claim 66, wherein $R_1$ is a substituted or unsubstituted normal, branched or cyclic $C_1$-$C_6$ alkyl group.

68. (Non-Entered Claim) The compound of claim 67, wherein $R_1$ is a normal or branched $C_1$-$C_4$ alkyl group.

69. (New) The compound of claim 1, wherein $R_1$ is a substituted or unsubstituted alkyl group.

70. (New) The compound of claim 69, wherein $R_1$ is a substituted or unsubstituted normal, branched or cyclic $C_1$-$C_6$ alkyl group.

71. (New) The compound of claim 70, wherein $R_1$ is a normal or branched $C_1$-$C_4$ alkyl group.